nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—EIF4E—renal system—rectum cancer	0.0408	0.0744	CbGeAlD
Sirolimus—EIF4E—female reproductive system—rectum cancer	0.0326	0.0596	CbGeAlD
Sirolimus—FGF2—smooth muscle tissue—rectum cancer	0.0258	0.0471	CbGeAlD
Sirolimus—FGF2—urethra—rectum cancer	0.0244	0.0445	CbGeAlD
Sirolimus—FGF2—mammalian vulva—rectum cancer	0.0232	0.0424	CbGeAlD
Sirolimus—MTOR—seminal vesicle—rectum cancer	0.0196	0.0357	CbGeAlD
Sirolimus—FGF2—vagina—rectum cancer	0.018	0.0328	CbGeAlD
Sirolimus—FKBP1A—seminal vesicle—rectum cancer	0.0176	0.0321	CbGeAlD
Sirolimus—MTOR—epithelium—rectum cancer	0.017	0.031	CbGeAlD
Sirolimus—MTOR—smooth muscle tissue—rectum cancer	0.0164	0.0299	CbGeAlD
Sirolimus—MTOR—renal system—rectum cancer	0.0158	0.0288	CbGeAlD
Sirolimus—FKBP1A—epithelium—rectum cancer	0.0153	0.0279	CbGeAlD
Sirolimus—SLC47A1—seminal vesicle—rectum cancer	0.0151	0.0276	CbGeAlD
Sirolimus—MTOR—mammalian vulva—rectum cancer	0.0147	0.0269	CbGeAlD
Sirolimus—FKBP1A—smooth muscle tissue—rectum cancer	0.0147	0.0269	CbGeAlD
Sirolimus—FKBP1A—renal system—rectum cancer	0.0142	0.0259	CbGeAlD
Sirolimus—FKBP1A—urethra—rectum cancer	0.0139	0.0254	CbGeAlD
Sirolimus—FKBP1A—mammalian vulva—rectum cancer	0.0133	0.0242	CbGeAlD
Sirolimus—MTOR—female reproductive system—rectum cancer	0.0126	0.023	CbGeAlD
Sirolimus—SLC47A1—renal system—rectum cancer	0.0122	0.0222	CbGeAlD
Sirolimus—SLCO1B1—renal system—rectum cancer	0.012	0.022	CbGeAlD
Sirolimus—SLC47A1—urethra—rectum cancer	0.012	0.0218	CbGeAlD
Sirolimus—FGF2—lymph node—rectum cancer	0.0116	0.0212	CbGeAlD
Sirolimus—MTOR—vagina—rectum cancer	0.0114	0.0208	CbGeAlD
Sirolimus—SLC47A1—mammalian vulva—rectum cancer	0.0114	0.0208	CbGeAlD
Sirolimus—FKBP1A—female reproductive system—rectum cancer	0.0114	0.0207	CbGeAlD
Sirolimus—FKBP1A—vagina—rectum cancer	0.0103	0.0187	CbGeAlD
Sirolimus—SLC47A1—female reproductive system—rectum cancer	0.00976	0.0178	CbGeAlD
Sirolimus—SLCO1B1—female reproductive system—rectum cancer	0.00964	0.0176	CbGeAlD
Sirolimus—SLC47A1—vagina—rectum cancer	0.00883	0.0161	CbGeAlD
Sirolimus—MTOR—lymph node—rectum cancer	0.00739	0.0135	CbGeAlD
Sirolimus—FKBP1A—lymph node—rectum cancer	0.00665	0.0121	CbGeAlD
Sirolimus—CYP3A5—renal system—rectum cancer	0.00618	0.0113	CbGeAlD
Sirolimus—SLC47A1—lymph node—rectum cancer	0.00571	0.0104	CbGeAlD
Sirolimus—CYP3A4—renal system—rectum cancer	0.00464	0.00846	CbGeAlD
Sirolimus—CYP3A5—vagina—rectum cancer	0.00447	0.00816	CbGeAlD
Sirolimus—ABCB1—seminal vesicle—rectum cancer	0.00407	0.00743	CbGeAlD
Sirolimus—CYP3A4—female reproductive system—rectum cancer	0.00371	0.00677	CbGeAlD
Sirolimus—ABCB1—epithelium—rectum cancer	0.00354	0.00645	CbGeAlD
Sirolimus—ABCB1—renal system—rectum cancer	0.00328	0.00599	CbGeAlD
Sirolimus—ABCB1—urethra—rectum cancer	0.00322	0.00588	CbGeAlD
Sirolimus—ABCB1—mammalian vulva—rectum cancer	0.00307	0.0056	CbGeAlD
Sirolimus—ABCB1—female reproductive system—rectum cancer	0.00263	0.00479	CbGeAlD
Sirolimus—EIF4E—Signaling by Insulin receptor—KRAS—rectum cancer	0.00245	0.00542	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TYMS—rectum cancer	0.00245	0.00542	CbGpPWpGaD
Sirolimus—ABCB1—vagina—rectum cancer	0.00238	0.00434	CbGeAlD
Sirolimus—MTOR—Alpha 6 Beta 4 signaling pathway—HRAS—rectum cancer	0.00235	0.0052	CbGpPWpGaD
Sirolimus—MTOR—ErbB2/ErbB3 signaling events—KRAS—rectum cancer	0.00232	0.00514	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC14A2—rectum cancer	0.00227	0.00502	CbGpPWpGaD
Sirolimus—MTOR—CXCR3-mediated signaling events—HRAS—rectum cancer	0.0021	0.00464	CbGpPWpGaD
Sirolimus—EIF4E—Signaling by Insulin receptor—HRAS—rectum cancer	0.00208	0.00461	CbGpPWpGaD
Sirolimus—FGF2—IRS-mediated signalling—NRAS—rectum cancer	0.00203	0.00449	CbGpPWpGaD
Sirolimus—MTOR—LKB1 signaling events—TP53—rectum cancer	0.00199	0.0044	CbGpPWpGaD
Sirolimus—MTOR—ErbB2/ErbB3 signaling events—HRAS—rectum cancer	0.00197	0.00437	CbGpPWpGaD
Sirolimus—FGF2—IRS-related events—NRAS—rectum cancer	0.00197	0.00437	CbGpPWpGaD
Sirolimus—FGF2—IRS-related events triggered by IGF1R—NRAS—rectum cancer	0.00196	0.00433	CbGpPWpGaD
Sirolimus—FGF2—IGF1R signaling cascade—NRAS—rectum cancer	0.0019	0.00421	CbGpPWpGaD
Sirolimus—FGF2—Insulin receptor signalling cascade—NRAS—rectum cancer	0.0019	0.00421	CbGpPWpGaD
Sirolimus—MTOR—ErbB Signaling Pathway—KRAS—rectum cancer	0.00186	0.00412	CbGpPWpGaD
Sirolimus—MTOR—mTOR signaling pathway—NRAS—rectum cancer	0.00184	0.00408	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—ITGA2—rectum cancer	0.00177	0.00391	CbGpPWpGaD
Sirolimus—EIF4E—BDNF signaling pathway—HRAS—rectum cancer	0.00175	0.00388	CbGpPWpGaD
Sirolimus—FGF2—IRS-mediated signalling—KRAS—rectum cancer	0.00175	0.00386	CbGpPWpGaD
Sirolimus—FGF2—IRS-related events—KRAS—rectum cancer	0.0017	0.00376	CbGpPWpGaD
Sirolimus—FGF2—IRS-related events triggered by IGF1R—KRAS—rectum cancer	0.00168	0.00372	CbGpPWpGaD
Sirolimus—MTOR—ErbB Signaling Pathway—TP53—rectum cancer	0.00166	0.00366	CbGpPWpGaD
Sirolimus—FGF2—Insulin receptor signalling cascade—KRAS—rectum cancer	0.00164	0.00363	CbGpPWpGaD
Sirolimus—FGF2—IGF1R signaling cascade—KRAS—rectum cancer	0.00164	0.00363	CbGpPWpGaD
Sirolimus—EIF4E—Insulin Signaling—HRAS—rectum cancer	0.00161	0.00356	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—KRAS—rectum cancer	0.00161	0.00355	CbGpPWpGaD
Sirolimus—MTOR—mTOR signaling pathway—KRAS—rectum cancer	0.00159	0.00351	CbGpPWpGaD
Sirolimus—MTOR—ErbB Signaling Pathway—HRAS—rectum cancer	0.00158	0.0035	CbGpPWpGaD
Sirolimus—FGF2—Signaling by Insulin receptor—NRAS—rectum cancer	0.00158	0.0035	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—TP53—rectum cancer	0.00158	0.00349	CbGpPWpGaD
Sirolimus—ABCB1—lymph node—rectum cancer	0.00154	0.0028	CbGeAlD
Sirolimus—MTOR—IRS-mediated signalling—NRAS—rectum cancer	0.00151	0.00333	CbGpPWpGaD
Sirolimus—FGF2—IRS-mediated signalling—HRAS—rectum cancer	0.00148	0.00328	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events—NRAS—rectum cancer	0.00146	0.00324	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events triggered by IGF1R—NRAS—rectum cancer	0.00145	0.00321	CbGpPWpGaD
Sirolimus—FGF2—IRS-related events—HRAS—rectum cancer	0.00144	0.00319	CbGpPWpGaD
Sirolimus—FGF2—IRS-related events triggered by IGF1R—HRAS—rectum cancer	0.00143	0.00317	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—rectum cancer	0.00143	0.00316	CbGpPWpGaD
Sirolimus—MTOR—Insulin receptor signalling cascade—NRAS—rectum cancer	0.00141	0.00313	CbGpPWpGaD
Sirolimus—MTOR—IGF1R signaling cascade—NRAS—rectum cancer	0.00141	0.00313	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.00141	0.00311	CbGpPWpGaD
Sirolimus—FGF2—Insulin receptor signalling cascade—HRAS—rectum cancer	0.00139	0.00308	CbGpPWpGaD
Sirolimus—FGF2—IGF1R signaling cascade—HRAS—rectum cancer	0.00139	0.00308	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—rectum cancer	0.00137	0.00302	CbGpPWpGaD
Sirolimus—FGF2—Signaling by Insulin receptor—KRAS—rectum cancer	0.00136	0.00301	CbGpPWpGaD
Sirolimus—MTOR—AMPK Signaling—TP53—rectum cancer	0.00136	0.00301	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—NRAS—rectum cancer	0.00135	0.003	CbGpPWpGaD
Sirolimus—MTOR—mTOR signaling pathway—HRAS—rectum cancer	0.00135	0.00298	CbGpPWpGaD
Sirolimus—MTOR—TSH signaling pathway—HRAS—rectum cancer	0.00135	0.00298	CbGpPWpGaD
Sirolimus—MTOR—IRS-mediated signalling—KRAS—rectum cancer	0.0013	0.00287	CbGpPWpGaD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—NRAS—rectum cancer	0.00129	0.00287	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—NRAS—rectum cancer	0.00129	0.00287	CbGpPWpGaD
Sirolimus—MTOR—CDC42 signaling events—HRAS—rectum cancer	0.00129	0.00285	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—NRAS—rectum cancer	0.00127	0.00282	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—NRAS—rectum cancer	0.00127	0.00281	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events—KRAS—rectum cancer	0.00126	0.00279	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—NRAS—rectum cancer	0.00125	0.00277	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events triggered by IGF1R—KRAS—rectum cancer	0.00125	0.00276	CbGpPWpGaD
Sirolimus—MTOR—Leptin signaling pathway—HRAS—rectum cancer	0.00122	0.00269	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—NRAS—rectum cancer	0.00122	0.00269	CbGpPWpGaD
Sirolimus—MTOR—Insulin receptor signalling cascade—KRAS—rectum cancer	0.00122	0.00269	CbGpPWpGaD
Sirolimus—MTOR—IGF1R signaling cascade—KRAS—rectum cancer	0.00122	0.00269	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—NRAS—rectum cancer	0.00121	0.00268	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.00121	0.00268	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.00121	0.00267	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—NRAS—rectum cancer	0.00121	0.00267	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—NRAS—rectum cancer	0.0012	0.00265	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—NRAS—rectum cancer	0.00118	0.00262	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.00118	0.00262	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—NRAS—rectum cancer	0.00117	0.0026	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—KRAS—rectum cancer	0.00116	0.00258	CbGpPWpGaD
Sirolimus—FGF2—Signaling by Insulin receptor—HRAS—rectum cancer	0.00116	0.00256	CbGpPWpGaD
Sirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—rectum cancer	0.00116	0.00256	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC14A2—rectum cancer	0.00113	0.00251	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—NRAS—rectum cancer	0.00113	0.0025	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—NRAS—rectum cancer	0.00113	0.0025	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—NRAS—rectum cancer	0.00113	0.0025	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—NRAS—rectum cancer	0.00112	0.00247	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—KRAS—rectum cancer	0.00111	0.00247	CbGpPWpGaD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—KRAS—rectum cancer	0.00111	0.00247	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—NRAS—rectum cancer	0.00111	0.00245	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—NRAS—rectum cancer	0.0011	0.00244	CbGpPWpGaD
Sirolimus—MTOR—IRS-mediated signalling—HRAS—rectum cancer	0.0011	0.00244	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—KRAS—rectum cancer	0.0011	0.00243	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—KRAS—rectum cancer	0.00109	0.00242	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—rectum cancer	0.00108	0.00239	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.00107	0.00237	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events—HRAS—rectum cancer	0.00107	0.00237	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—rectum cancer	0.00106	0.00235	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—KRAS—rectum cancer	0.00105	0.00232	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—NRAS—rectum cancer	0.00104	0.00231	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—KRAS—rectum cancer	0.00104	0.00231	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—KRAS—rectum cancer	0.00104	0.0023	CbGpPWpGaD
Sirolimus—MTOR—Insulin receptor signalling cascade—HRAS—rectum cancer	0.00103	0.00229	CbGpPWpGaD
Sirolimus—MTOR—IGF1R signaling cascade—HRAS—rectum cancer	0.00103	0.00229	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—KRAS—rectum cancer	0.00103	0.00228	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.00103	0.00228	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—KRAS—rectum cancer	0.00102	0.00225	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.00102	0.00225	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—KRAS—rectum cancer	0.00101	0.00224	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—NRAS—rectum cancer	0.001	0.00222	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—NRAS—rectum cancer	0.000999	0.00221	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—HRAS—rectum cancer	0.00099	0.00219	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—rectum cancer	0.000973	0.00215	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—KRAS—rectum cancer	0.000971	0.00215	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—KRAS—rectum cancer	0.000971	0.00215	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—KRAS—rectum cancer	0.000971	0.00215	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—KRAS—rectum cancer	0.000962	0.00213	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—NRAS—rectum cancer	0.000961	0.00213	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—KRAS—rectum cancer	0.000954	0.00211	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—KRAS—rectum cancer	0.00095	0.0021	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—HRAS—rectum cancer	0.000947	0.0021	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—NRAS—rectum cancer	0.000946	0.00209	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—HRAS—rectum cancer	0.000932	0.00206	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—rectum cancer	0.00093	0.00206	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—HRAS—rectum cancer	0.00093	0.00206	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—rectum cancer	0.000916	0.00203	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.000914	0.00202	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—NRAS—rectum cancer	0.000903	0.002	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—NRAS—rectum cancer	0.000899	0.00199	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—KRAS—rectum cancer	0.000899	0.00199	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—NRAS—rectum cancer	0.000894	0.00198	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—HRAS—rectum cancer	0.00089	0.00197	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—NRAS—rectum cancer	0.00089	0.00197	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—HRAS—rectum cancer	0.000886	0.00196	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—HRAS—rectum cancer	0.000882	0.00195	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—HRAS—rectum cancer	0.000877	0.00194	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.000877	0.00194	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—HRAS—rectum cancer	0.000865	0.00191	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000865	0.00191	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—KRAS—rectum cancer	0.000864	0.00191	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.00086	0.0019	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—HRAS—rectum cancer	0.000859	0.0019	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—rectum cancer	0.000837	0.00185	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—NRAS—rectum cancer	0.000837	0.00185	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—NRAS—rectum cancer	0.000837	0.00185	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—NRAS—rectum cancer	0.00083	0.00184	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—KRAS—rectum cancer	0.000827	0.00183	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—HRAS—rectum cancer	0.000825	0.00183	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—HRAS—rectum cancer	0.000825	0.00183	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.000825	0.00183	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—NRAS—rectum cancer	0.000822	0.00182	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—NRAS—rectum cancer	0.000819	0.00181	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—rectum cancer	0.000818	0.00181	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—HRAS—rectum cancer	0.000818	0.00181	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—KRAS—rectum cancer	0.000814	0.0018	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.000812	0.0018	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.000811	0.00179	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—HRAS—rectum cancer	0.000807	0.00179	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—rectum cancer	0.000782	0.00173	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—KRAS—rectum cancer	0.000777	0.00172	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—NRAS—rectum cancer	0.000775	0.00171	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—KRAS—rectum cancer	0.000774	0.00171	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—rectum cancer	0.000774	0.00171	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—KRAS—rectum cancer	0.00077	0.0017	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—NRAS—rectum cancer	0.000769	0.0017	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—KRAS—rectum cancer	0.000766	0.0017	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—HRAS—rectum cancer	0.000764	0.00169	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.000755	0.00167	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—rectum cancer	0.000742	0.00164	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—HRAS—rectum cancer	0.000735	0.00163	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000731	0.00162	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—rectum cancer	0.000727	0.00161	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—HRAS—rectum cancer	0.000722	0.0016	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—KRAS—rectum cancer	0.000721	0.00159	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—KRAS—rectum cancer	0.000721	0.00159	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—rectum cancer	0.000721	0.00159	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—KRAS—rectum cancer	0.000714	0.00158	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—KRAS—rectum cancer	0.000708	0.00157	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—KRAS—rectum cancer	0.000705	0.00156	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—rectum cancer	0.000703	0.00156	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—HRAS—rectum cancer	0.000692	0.00153	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—KRAS—rectum cancer	0.000667	0.00148	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—HRAS—rectum cancer	0.000664	0.00147	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—KRAS—rectum cancer	0.000661	0.00146	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—HRAS—rectum cancer	0.000661	0.00146	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—HRAS—rectum cancer	0.000657	0.00146	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—rectum cancer	0.000657	0.00146	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—HRAS—rectum cancer	0.000654	0.00145	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—HRAS—rectum cancer	0.000651	0.00144	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000642	0.00142	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.000638	0.00141	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.000613	0.00136	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—HRAS—rectum cancer	0.000613	0.00136	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—HRAS—rectum cancer	0.000613	0.00136	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—HRAS—rectum cancer	0.000607	0.00134	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.000602	0.00133	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—HRAS—rectum cancer	0.000599	0.00133	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—NRAS—rectum cancer	0.00057	0.00126	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—HRAS—rectum cancer	0.000567	0.00125	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—HRAS—rectum cancer	0.000562	0.00124	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000542	0.0012	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—NRAS—rectum cancer	0.000496	0.0011	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—KRAS—rectum cancer	0.000491	0.00109	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—rectum cancer	0.000465	0.00103	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—NRAS—rectum cancer	0.000459	0.00102	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—NRAS—rectum cancer	0.000438	0.00097	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—KRAS—rectum cancer	0.000427	0.000945	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—NRAS—rectum cancer	0.000421	0.000932	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—HRAS—rectum cancer	0.000417	0.000923	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—KRAS—rectum cancer	0.000395	0.000875	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KRAS—rectum cancer	0.000377	0.000835	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—rectum cancer	0.000363	0.000804	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KRAS—rectum cancer	0.000362	0.000802	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—rectum cancer	0.000336	0.000744	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—NRAS—rectum cancer	0.000325	0.00072	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—rectum cancer	0.000321	0.00071	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—NRAS—rectum cancer	0.000312	0.000691	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NRAS—rectum cancer	0.000311	0.000688	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—rectum cancer	0.000308	0.000682	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NRAS—rectum cancer	0.000297	0.000657	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.000292	0.000646	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TYMS—rectum cancer	0.000291	0.000643	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—rectum cancer	0.00028	0.00062	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—rectum cancer	0.000269	0.000595	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—rectum cancer	0.000268	0.000592	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TYMS—rectum cancer	0.000267	0.00059	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.000259	0.000574	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—rectum cancer	0.000256	0.000566	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NRAS—rectum cancer	0.000255	0.000565	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—rectum cancer	0.000238	0.000527	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRAS—rectum cancer	0.000236	0.000522	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—rectum cancer	0.000229	0.000506	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—rectum cancer	0.000228	0.000504	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—rectum cancer	0.000227	0.000503	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—rectum cancer	0.00022	0.000486	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—rectum cancer	0.000218	0.000482	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—rectum cancer	0.000217	0.000481	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—rectum cancer	0.000203	0.000449	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TYMS—rectum cancer	0.000193	0.000427	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—rectum cancer	0.000189	0.000419	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—rectum cancer	0.000187	0.000415	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—rectum cancer	0.000187	0.000413	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—rectum cancer	0.000175	0.000387	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—rectum cancer	0.000172	0.000382	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—rectum cancer	0.000167	0.000369	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—rectum cancer	0.000165	0.000365	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—rectum cancer	0.000163	0.000361	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—rectum cancer	0.000159	0.000353	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—rectum cancer	0.000151	0.000333	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TYMS—rectum cancer	0.000145	0.000322	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—rectum cancer	0.000142	0.000314	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—rectum cancer	0.000139	0.000307	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—rectum cancer	0.000128	0.000283	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—rectum cancer	0.000126	0.000279	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—rectum cancer	0.000122	0.000271	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—rectum cancer	0.000121	0.000267	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—rectum cancer	0.000105	0.000233	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—rectum cancer	9.37e-05	0.000207	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMS—rectum cancer	8.96e-05	0.000198	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—rectum cancer	8.96e-05	0.000198	CbGpPWpGaD
